**Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes.**
Impact factor: 2.225

**A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe.**
Vaccine. 2015 Apr 7. pii: S0264-410X(15)00393-X. [Epub ahead of print]
Impact factor: 3.492

**Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-γ in QuantiFERON assays in healthy persons.**
Penn-Nicholson A, Nemes E, Hanekom WA, Hatherill M, Scriba TJ.
Impact factor: 3.033

**Innovative clinical trial designs to rationalize TB vaccine development.**
Impact factor: 3.033

**Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients.**
Wood RC, Luabeya AK, Weigel KM, Wilbur AK, Jones-Engel L, Hatherill M, Cangelosi GA.
Impact factor: 2.927

**A Review and Proposed Approach to the Neutrophilic Dermatoses of Childhood.**
Impact factor: 1.041

**Tuberculosis vaccines: time for a global strategy.**
Kaufmann SH, Evans TG, Hanekom WA.
Impact factor: 10.757

**T cells and adaptive immunity to Mycobacterium tuberculosis in humans.**
Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE.
Impact factor: 7.053
The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents.
Impact factor: 11.041

The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination.
Impact Factor: 6.407

Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.
Impact factor: 2.225

Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood.
Impact factor: 3.066

Qualification of a Whole Blood Intracellular Cytokine Staining Assay To Measure Mycobacteria-Specific CD4 and CD8 T Cell Immunity by Flow Cytometry.
Impact factor: 2.225

Differential leuckocyte counting and immunophenotyping in cryopreserved ex-vivo whole blood.
Impact factor: 3.711

Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial.
Impact factor: 3.73

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.
Impact factor: 3.025

The Combined Use of M. tuberculosis-specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of
MASTER PUBLICATION LIST

Active Tuberculosis.
Impact factor: 9.374

The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8 T cell responses.
Vaccine. 2014 Sep 9.
Impact factor: 3.492

Time to Symptom Resolution in Young Children Treated for Pulmonary Tuberculosis.
Impact factor: 3.569

A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community.
Geldenhuys HD, Whitelaw A, Tameris MD, Van As D, Luabeya KK, Mahomed H, Hussey G, Hanekom WA, Hatherill M.
Impact factor: 3.024

Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Impact factor: 3.492

Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study.
Impact factor: 5.854

Patients with Tuberculosis Disease Have Mycobacterium tuberculosis-Specific CD8 T Cells with a Pro-Apoptotic Phenotype and Impaired Proliferative Capacity, Which Is Not Restored following Treatment.
Day CL, Moshi ND, Abrahams DA, van Rooyen M, O’rie T, de Kock M, Hanekom WA.
Impact factor: 3.73

Maturation of Innate Responses to Mycobacteria over the First Nine Months of Life.
Impact factor: 5.52

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
Impact factor: 3.73
**Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants.**
Impact factor: 5.848

**The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacilli Calmette-Guérin vaccination.**
Impact factor: 6.407

**TB Vaccines & Prevention of Infection.**
Impact factor: 16.417

**High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.**
Impact factor: 51.658

**St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death.**
Impact factor: 3.73

**Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa.**
Impact factor: 3.73

**Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.**
Impact factor: 3.025

**Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.**

**Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.**
Impact factor: 4.565

**Pediatric intensive care in South Africa: an account of making optimum use of limited resources at the Red Cross War Memorial Children’s Hospital.***

Argent AC, Ahrens J, Morrow BM, Reynolds LG, Hatherill M, Salie S, Benatar SR.
Impact factor: 2.354

Impact factor: 4.578

**Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity.**

Impact factor: 4.587

**Effect of Isoniazid Therapy for Latent Tuberculosis Infection on QuantiFERON-TB Gold In-tube Responses in Tuberculin Skin Test Positive Adults in a High Tuberculosis Incidence Area: A Controlled Study.**

Chest. 2013 Oct
Impact factor: 5.854

**Knowledge and acceptability of patient-specific infection control measures for pulmonary tuberculosis.**

Impact factor: 2.731

**Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function.**

Impact factor: 4.97

**Screening for TB in high school adolescents in a high burden setting in South Africa**

Tuberculosis. 2013 May;93 (2013) 357-362
Impact factor: 3.033

**Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.**

Impact factor: 39.06

**Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.**

Impact factor: 3.033

**Longitudinal Changes in CD4+ T-Cell Memory Responses Induced by BCG Vaccination of Newborns.**
Impact factor: 5.848

Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease.
Eur J Immunol. 2013 Jun
Impact factor: 4.97

TB incidence in an adolescent cohort in South Africa.
Impact factor: 3.73

Induction and Regulation of T Cell Immunity by the Novel TB Vaccine M72/AS01 in South African Adults.
Impact factor: 11.041

Vaccine-induced immunity in early life.
Kollmann TR, Levy O, Hanekom W. Vaccine. 2013 May
Impact factor: 3.492

Varicella Zoster-Specific CD4+Foxp3+ T Cells Accumulate after Cutaneous Antigen Challenge in Humans.
Impact factor:

Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis.

A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population.
Immunogenetics. 2013 May;65(5):357-70.

Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa.
PLoS One. 2013 Sep
Consensus Statement on Diagnostic End Points for Infant Tuberculosis Vaccine Trials.
Impact factor: 9.374

Sputum induction for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis.
Impact factor: 3.024

Diagnostic Features Associated With Culture of Mycobacterium tuberculosis Among Young Children in a Vaccine Trial Setting.
Impact factor: 3.569

Safety and tolerability of sputum induction in adolescents and adults with suspected pulmonary tuberculosis.
Impact factor: 3.024

Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria.
Impact factor: 2.225

A phase IIb Trial of the new TB Vaccine, MVA85A, in HIV and/or M. Tuberculosis Infected Adults.
Impact factor: 2.731

SATVI - after 10 years closing in on a new and better vaccine to prevent tuberculosis.
Impact factor: 1.702

Vaccine trials in the developing world: operational lessons learnt from a phase IV poliomyelitis vaccine trial in South Africa.
Impact factor: 3.492

Predictive Value of Recent QuantiFERON Conversion for Tuberculosis Disease in Adolescents.
Impact factor: 11.041

The Influence of Bacille Calmette-Guerin Vaccine Strain on the Immune Response against Tuberculosis: A Randomized Trial.

Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells.

**HIV-1 infection alters CD4+ memory T-cell phenotype at the site of disease in extrapulmonary tuberculosis.**

**Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifampentine.**

**Meeting report: The International Conference on Human Immunity to Tuberculosis.**

**Key issues in the clinical development and implementation of TB vaccines in South Africa.**

**Detection and treatment of subclinical tuberculosis.**

**A comparative analysis of polyfunctional T cells and secreted cytokines induced by Bacille Calmette-Guérin immunisation in children and adults.**

**Genetic Variation in TLR Genes in Ugandan and South African Populations and Comparison with HapMap Data.**

**Prospects for elimination of childhood tuberculosis: the role of new vaccines.**
Hatherill M. Arch Dis Child. 2011 Sep;96(9):851-6.
Impact factor: 3.051

**Safety and tolerability of sputum induction in adolescents and adults with suspected pulmonary tuberculosis.**
Impact factor: 3.024

**Phenotypic variability in childhood TB: Implications of diagnostic endpoints in tuberculosis vaccine trials.**
Impact factor: 3.492

**Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants.**

**Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis.**

**Prospects for a new, safer and more effective TB vaccine.**

**Tuberculin skin test and QuantiFERON assay in young children investigated for tuberculosis in South Africa.**

**Risky Behaviour and Psychosocial Correlates in Adolescents – is there a link with Tuberculosis?**

**Functional Capacity of Mycobacterium tuberculosis-Specific T Cell Responses in Humans Is Associated with Mycobacterial Load**

**HIV specific gag responses in early infancy correlate with clinical outcome and inversely with viral load**

**Predictive factors for latent tuberculosis infection among adolescents in a high burden area in South Africa.**

**Developing vaccinology expertise for Africa: six years and counting.**

**The tuberculin skin test versus Quantifieron TB Gold in predicting tuberculosis disease in an adolescent cohort study in South Africa.**

**The Utility of an Interferon Gamma Release Assay for Diagnosis of Latent Tuberculosis Infection and Disease in Children: A Systematic Review and Meta-analysis.**
MASTER PUBLICATION LIST

Impact factor: 3.569

Dominant TNF-α (+) Mycobacterium tuberculosis-specific CD4 (+) T cell responses discriminate between latent infection and active disease.
Impact factor: 22.864

Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa.
Impact factor: 2.61

Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses.

Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding.

Association of Human TLR1 & TLR6 Deficiency with Altered Immune Responses to BCG Vaccination in South African Infants.

Immunological biomarkers in Tuberculosis.

Induction of granulysin and perforin cytolytic mediator expression in 10-week-old infants vaccinated with BCG at birth.

PUBLICATION LIST 2010 (15)

Novel vaccine prime and selective BCG boost: a new tuberculosis vaccine strategy for infants of HIV-infected mothers.
Impact factor: 3.492

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.
Impact factor: 4.97

Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease.
Specific T Cell Frequency and Cytokine Expression Profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns.
Impact factor: 11.041

The Tuberculin Skin Test: a comparison of reading with a ruler to reading with a calliper.
Impact factor: 2.61

Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa.
Impact factor: 2.61

CD4 and CD8 T Cell Responses to Mycobacterial Antigens in African Children.
Impact factor: 11.041

The Novel TB Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4 and CD8 T Cells in Adults.
Impact factor: 11.041

Tuberculosis research update.
Impact factor: 2.938

Single nucleotide polymorphisms in toll-like receptor 6 are associated with altered lipopeptide- and mycobacteria-induced interleukin-6 secretion.
Impact factor: 3.675
Comparison of polyclonal expansion methods to improve the recovery of cervical cytobrush-derived T cells from the female genital tract of HIV-infected women.

Tuberculin skin test and in-vitro assays provide complementary measures of anti-mycobacterial immunity in children and adolescents.

STRUCTURED APPROACHES FOR THE SCREENING AND DIAGNOSIS OF CHILDHOOD TUBERCULOSIS IN A HIGH PREVALENCE REGION OF SOUTH AFRICA.

THE POTENTIAL IMPACT OF HELMINTH INFECTION ON TRIALS OF NOVEL TUBERCULOSIS VACCINES.

INDUCED SPUTUM OR GASTRIC LAVAGE FOR COMMUNITY-BASED DIAGNOSIS OF CHILDHOOD PULMONARY TUBERCULOSIS?

COMPARISON OF MANTOUX AND TINE TUBERCULIN SKIN TESTS IN BCG-VACCINATED CHILDREN INVESTIGATED FOR TUBERCULOSIS.

DELAYING BCG VACCINATION FROM BIRTH TO 10 WEEKS OF AGE MAY RESULT IN AN ENHANCED MEMORY CD4 T CELL RESPONSE.

HIV-1 INFECTION IN INFANTS SEVERELY IMPAIRS THE IMMUNE RESPONSE INDUCED BY BACILLE CALMETTE-GUÆRIN VACCINE.

SIGNIFICANTLY SKewed MEMORY CD8+ T cell subsets in HIV-1 infected infants during the first year of life.

NEW VACCINES AGAINST TUBERCULOSIS.

TWO LOCI CONTROL TUBERCULIN SKIN TEST REACTIVITY IN AN AREA HYPERENDEMIC FOR TUBERCULOSIS.
**HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria.**

**Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract.**

**Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.**

**Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa.**

**Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth.**

**Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting.**

**Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response.**

**Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial.**

**Are adolescents ready for tuberculosis vaccine trials?**

**Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations.**

**Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.**

*Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles.*

Evaluating the quality of informed consent in a vaccine field trial in a developing country setting.

*CD8+ T-cell interleukin-7 receptor alpha expression as a potential indicator of disease status in HIV-infected children.*

Exposure of cord blood to Mycobacterium bovis BCG induces an innate response but not a T-cell cytokine response.

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

A comparison of IFNgamma detection methods used in tuberculosis vaccine trials.

Influence of BCG vaccine strain on the immune response and protection against tuberculosis.

Immunological protection against tuberculosis.

Prospects for new tuberculosis vaccines.

Tuberculosis contacts and prophylaxis.

Childhood tuberculosis: old and new vaccines.
Hussey G, Hawkridge T, Hanekom W.
Determining causes of mortality in children enrolled in a vaccine field trial in a rural area in the Western Cape Province of South Africa.
Impact factor: 1.254

Isolation of non-tuberculous mycobacteria in children investigated for pulmonary tuberculosis.
Impact factor: 3.73

The impact of a change in bacille Calmette-Guérin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa.
Impact factor: 3.569

Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection.
Impact factor: 2.61

Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response.
Impact factor: 5.52

Quantitative and functional differences between peripheral blood myeloid dendritic cells from patients with pleural and parenchymal lung tuberculosis.

The effect of bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants.